
    
      This was a phase Ia, multicenter, open-label, dose-escalation clinical study to evaluate the
      safety, tolerability, pharmacokinetics and pharmacodynamics characteristics of HLX01
      injection in patients with CD20-positive B-cell lymphomas.
    
  